posted
Topcat, I put this on my regular broker yesterday. He got back with me latter in the day to say he is very impressed. One of the things he was most impressed with was MARR.
He wasn't that worried about the number of outstanding shares because MARR owns 27% of the company and ready to handle China. This was a major plus.
quote:Originally posted by Topcat: No great movement, was up 25% premarket, but never made it??
Any idea why ?
I'd feel lots better if it wasn't a AMEX stock. For that reason I think the stock has to show earnings before you get any real jumps. Good luck.
IP: Logged |
posted
The company will host a conference call featuring a report by its Chairman and interim Chief Executive Officer, Roger I. Gale, at 11:00 AM Eastern Time on Friday, October 14, 2005, followed by a question and answer session. The call can be accessed in the U.S. by dialing 1-800-573-4842 and outside of the U.S. 1-617-224-4327 and entering conference identification number 65101749.
posted
Topcat, there's so much news I don't know where they will start. I guess everyone wants an update on the plant in China and the China CDC. Next would be the Manufacturing facility in the US. Then the state of the Africian nations. Last (but probably first) would be the new management team. A lot have been said about MARR taking over for sales and marketing now that the Scientific part is essentially finished.
posted
More good news yesterday.... sorry for the late post.
Press Release Source: Calypte Biomedical
Calypte Aware(TM) BSP Passes Malaysian Government Evaluation Tuesday October 11, 8:30 am ET
LAKE OSWEGO, Ore., Oct. 11 /PRNewswire-FirstCall/ -- Calypte Biomedical Corporation (Amex: HIV - News) today announced that it has received notification that Aware(TM) BSP, its rapid blood test for HIV-1 and HIV-2 antibodies, has been successfully evaluated by government agencies in Malaysia. ADVERTISEMENT
In Malaysia, favorable government evaluation is generally requested although not strictly required to market HIV tests.
Aware(TM) BSP is a twenty-minute rapid test designed to detect HIV antibodies in whole blood, serum, or plasma. It is one test in a line of three such assays, the other two being designed to detect HIV antibodies in oral fluid and urine. The health authorities in Malaysia have not evaluated non-blood HIV tests in the past, and are determining how such evaluations should be undertaken.
"We're delighted our Aware HIV-1/2 products continue to perform well in clinical evaluations around the world. Now that the Aware BSP test has passed this evaluation, we look forward to working with Belantara Sains Teknologi (BST), our Malaysian distributor, to commercially launch the product," stated Roger Gale, Calypte's Chairman and Chief Executive Officer.
Christine Lim, BST's Chief Operating Officer, added, "The support that we had from Calypte Biomedical prompted us to have these kits evaluated via a recognized body. This has created a higher confidence for our customers who have had some bad experiences from the unevaluated kits which are so vastly available in this eastern part of the world. Now we can look forward to working more closely not only with the Ministry of Health but especially with the health clinics in the remote areas, where a kit as convenient as this is certainly useful, practical and most importantly, reliable."
Malaysia, with a population of roughly 24 million, has an estimated 55,000 HIV infections, according to the CIA Fact book, 2003.
About Calypte Biomedical:
Calypte Biomedical Corporation is a US-based healthcare company focused on the development and commercialization of diagnostic testing products for the detection of sexually transmitted diseases. Calypte specializes in novel tests such as the HIV-1 BED Incidence EIA and is engaged in developing and commercializing new diagnostic test products for the rapid detection of HIV and other sexually transmitted diseases, several of which do not require blood samples. Calypte believes that there is a significant need for rapid detection of such diseases globally to control their proliferation, particularly in lesser-developed countries, which lack the medical infrastructure to support laboratory-based testing. Calypte believes that testing for HIV and other sexually transmitted infectious diseases may make important contributions to public health, and could increase the likelihood of treating those with undetected HIV and other sexually transmitted diseases.
IP: Logged |
posted
Topcat, The CC was a non-event. Little was learned. The new players were introduced, period. The real CC will be mid-november. We should have financial news at that time.
posted
Time to bring this thread up again. Movement today was to .23 on no news, nothing, NADA. Beats the hell out of me. But since I'm in as a long holder it's nice to see movement of this kind.
posted
Poker, I wish I knew. But someone knows and they're acting on it. Or, this is a buying frenzy by folks that don't want to get left out. I'm going to hold till news about China, etc. This isn't a short term stock IMO.
posted
Chian approval received, goin to be hot today !!!
Calypte Announces Submission of Application to Chinese SFDA Thursday January 12, 8:00 am ET For Approval of its Aware(TM) OMT Oral Fluid HIV-1/2 Rapid Diagnostic Test
LAKE OSWEGO, Ore., Jan. 12 /PRNewswire-FirstCall/ -- Calypte Biomedical Corporation (Amex: HIV - News) today announced that it has received notification from the Beijing Drug Administration (BDA) that its application for approval in China of its Aware(TM) OMT (Oral) HIV-1/2 rapid test has been formally accepted. The Company submitted its application to the BDA on December 27, 2005. According to Chinese drug registration regulations, the BDA is responsible for receiving applications on behalf of the State Food and Drug Administration of China (SFDA). Formal acceptance means that the BDA has completed an initial review of the application and deems the application to be sufficiently complete and in compliance with regulations to allow the application to advance into the formal review process. ADVERTISEMENT
Roger Gale, Chairman and Chief Executive Officer of Calypte said, "China is one of the countries that may experience a significant spread of HIV unless the government can follow through on its plans to curtail the growth of this problem. China has an acknowledged testing gap and has officially announced plans to offer voluntary HIV testing to its entire 1.36 billion-population, with particular emphasis on certain key groups, for which we believe our test is particularly appropriate. We believe that the only effective way to manage such testing thresholds is to utilize trained non-professionals to administer a program based on safe, non-blood or alternative fluid -- oral fluid -- testing."
Dr. Ron Mink, Chief Science Officer of Calypte added, "With the acceptance of our application by the BDA, Calypte has accomplished a key milestone in obtaining approval to sell our Aware(TM) HIV 1/2 OMT Rapid oral fluid product in the Chinese market. We believe that this product will have great appeal in China by virtue of its superior performance, competitive cost and advantages afforded by the use of oral fluid samples over other products available now or anticipated in the near future, in China."
About China:
China has a population of approximately 1.4 billion. According to a joint China, World Health Organization and UNAIDS epidemiological survey there were a reported 840,000 adults and children in China living with HIV/AIDS in 2003. Some experts have predicted that the number of infections by 2010 might exceed 15 million. The annual AIDS testing level is currently estimated at 1.5% of the population but is expected to grow -- partially due to a formal focus on mandatory testing in large markets such as population control, prisons and immigration and partially due to the Chinese government's program to offer voluntary HIV testing to its entire population.
IP: Logged |
posted
I dropped the ball on this one....tried to pinch a penny and get in at $0.14 instead of taking the $0.15 a month ago with $3,000 for a long position.
IP: Logged |
posted
R1Man, I hope you got back in. This has been an incredible week. 1.36 Billion Chinese lining up to be tested. You may be looking at $1 through your rear view mirror.
posted
Yahoo! My Yahoo! Mail Make Yahoo! your home page Sign In New User?Sign Up Finance Home - Help
Welcome [Sign In] To track stocks & more, Register Financial News Enter symbol(s) BasicPerformanceReal-time MktDetailedChartResearchOptionsOrder Book Symbol Lookup
Calypte Introduces Over-the-Counter Rapid Oral HIV Test Thursday January 19, 8:00 am ET Aware(TM) OMT (Oral Fluid) HIV-1/2 Rapid Diagnostic Test Registered in the United Arab Emirates
LAKE OSWEGO, Ore., Jan. 19 /PRNewswire-FirstCall/ -- Calypte Biomedical Corporation (Amex: HIV - News) today announced the introduction of an over-the- counter (OTC) version of the Aware(TM) Oral Fluid HIV-1/2 Rapid Diagnostic Test. Calypte expects to initially launch the sale of this product in over-the-counter markets in the United Arab Emirates, where the product has been registered, and then plans to distribute it throughout the entire Middle East as additional registrations and/or approvals are obtained. ADVERTISEMENT
The OTC Aware Oral Fluid HIV-1/2 Rapid Diagnostic Test will be distributed by Joseph and Gionis, Calypte's exclusive distributor for 22 Middle Eastern countries with a population of approximately 465 million people. According to the December 2004 UNAIDS report, there are between 230,000 and 1.5 million adults and children living with HIV within this region, of which nearly half are women.
Mr. Roger Gale, Chairman and Chief Executive Officer of Calypte stated, "We are extremely pleased to launch our newest product, an Aware Oral Fluid HIV-1/2 Rapid Diagnostic Test designed for use in an over-the-counter setting. We believe that this product will add another tool to increase detection and combat the spread of HIV virus and that the combination of an over-the-counter product with safe, oral fluid detection is well suited to reach the greatest number of individuals within the Middle Eastern countries. We look forward to a productive relationship with our newest distributor, Joseph and Gionis, as it continues to utilize its expertise in regulatory pharmaceutical and governmental affairs to facilitate the regulatory process in additional countries within its territory."
Mr. Gale, concluded, "Our launch of this over-the-counter product coincides with Arab Health, the largest Healthcare Exhibition in the Middle East, being held in Dubai, January 22-25th. We have already shipped the initial order to Joseph and Gionis in conjunction with this Exhibition and we believe we have sufficient inventory in stock to satisfy anticipated initial sales of this innovative product."
About Joseph and Gionis LLC
Joseph and Gionis is a global biotechnology consulting and distribution firm with offices in Newport Beach, California and the United Arab Emirates, specializing in new scientific developments which contribute to public health and welfare.
About Calypte Biomedical:
Calypte Biomedical Corporation is a US-based healthcare company focused on the development and commercialization of diagnostic testing products for the detection of sexually transmitted diseases. Calypte specializes in novel tests such as the HIV-1 BED Incidence EIA and is engaged in developing and commercializing new diagnostic test products for the rapid detection of HIV and other sexually transmitted diseases, several of which do not require blood samples. Calypte believes that there is a significant need for rapid detection of such diseases globally to control their proliferation, particularly in lesser-developed countries, which lack the medical infrastructure to support laboratory-based testing. Calypte believes that testing for HIV and other sexually transmitted infectious diseases may make important contributions to public health, and could increase the likelihood of treating those with undetected HIV and other sexually transmitted diseases.
Statements in this press release that are not historical facts are forward-looking statements within the meaning of the Securities Act of 1933, as amended. Those statements include statements regarding the intent, belief or current expectations of the Company and its management. Such statements reflect management's current views, are based on certain assumptions and involve risks and uncertainties. Actual results, events, or performance may differ materially from the above forward-looking statements due to a number of important factors, and will be dependent upon a variety of factors, including, but not limited to, the Company's ability to obtain additional financing, if and as needed, and access funds from its existing financing arrangements that will allow it to continue its current and future operations and whether demand for its test products in domestic and international markets will generate sufficient revenues to achieve positive cash flow and profitability. The Company undertakes no obligation to publicly update these forward-looking statements to reflect events or circumstances that occur after the date hereof or to reflect any change in the Company's expectations with regard to these forward-looking statements or the occurrence of unanticipated events. Factors that may impact the Company's success are more fully disclosed in the Company's most recent public filings with the U.S. Securities and Exchange Commission ("SEC"), including its annual report on Form 10-KSB/A (No. 2) for the year ended December 31, 2004 and its subsequent filings with the SEC.
Company Contact: Investor Relations Contact: Theodore R Gwin, Tim Clemensen, Chief Financial Officer Rubenstein Investor Relations (971) 204-0282 Phone: (212) 843-9337 email: tgwin*calypte.com email
IP: Logged |
ITEM 3.01 NOTICE OF DELISTING OR FAILURE TO SATISFY A CONTINUED LISTING RULE OR STANDARD; TRANSFER OF LISTING. On February 2, 2006 Calypte Biomedical Corporation (the "Company") received a letter from the American Stock Exchange (the "Exchange") notifying the Company that it does not satisfy certain of the Exchange's continued listing standards as set forth in Part 10 the American Stock Exchange Company Guide (the "Company Guide") and that the Exchange staff has, therefore, determined to initiate delisting proceedings with respect to the Company's common stock.
Specifically, the Exchange noted that the Company is not in compliance with Section 1003(a)(i) with shareholders' equity of less than $2,000,000 and losses from continuing operations and/or net losses in two out of its three most recent fiscal years; Section 1003(a)(ii) with shareholders' equity of less than $4,000,000 and losses from continuing operations and/or net losses in three out of its four most recent fiscal years; Section 1003(a)(iii) with shareholders' equity of less than $6,000,000 and losses from continuing operations and/or net losses in its five most recent fiscal years; and Section 1003(a)(iv) with losses which are so substantial in relation to its overall operations or its existing financial resources, or its financial condition has become so impaired that it appears questionable, in the opinion of the Exchange, as to whether the Company will be able to continue operations and/or meet its obligations as they mature.
The Company has until February 10, 2006 to request an appeal of the Exchange's determination, and plans to request a hearing before a committee of the Exchange. The Company expects that such a hearing would be scheduled within 45 days of its request. There can be no assurance that the Company's appeal will result in the continued listing of its common stock on the Exchange. If its common stock is delisted from the Exchange after the hearing, it would likely trade on the NASD Over the Counter Bulletin Board.
IP: Logged |
UBBFriend: Email this page to someone!
Printer-friendly view of this topic
![[Eek!]](eek.gif)
![[Roll Eyes]](rolleyes.gif)
![[Big Grin]](biggrin.gif)
![[Razz]](tongue.gif)
![[Cool]](cool.gif)
